Herpes zoster prevention in multiple sclerosis and neuromyelitis optica spectrum disorders
, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 2, 16
Abstract
A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society, the Polish Society of Family Medicine, and the Polish Society of Vaccinology has developed a consensus on supplementary data to the recommendations of the expert group of the Polish Society of Vaccinology, the Polish Society of Family Medicine, the Polish Dermatological Society, the Polish Association for the Study of Pain, and the Polish Neurological Society, and ECTRIMS/EAN of 2023 with regard to the currently available in Poland recombinant herpes zoster vaccine (RZV). It is intended for the prevention of herpes zoster and postherpetic neuralgia in individuals aged > 50 and individuals aged ≥ 18 who belong to herpes zoster risk groups. In Poland it is available with 50% reimbursement exclusively for patients aged 65 and older who have an increased risk of developing herpes zoster.
This statement is based on the literature available as of 12 July 2024. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccine comes from clinical trials which have been reviewed, published and approved by the regulatory authorities and an increasing number of recommendations that might have an impact on real world data.
Keywords: herpes zostermultiple sclerosisneuromyelitis optica spectrum disordersrisk of herpes zosterindications for vaccination
References
- Harder T, Siedler A. Systematic Review and Meta-analysis of Chickenpox Vaccination and Risk of Herpes Zoster: A Quantitative View on the "Exogenous Boosting Hypothesis". Clin Infect Dis. 2019; 69(8): 1329–1338.
- Kuchar E, Rudnicka L, Kocot-Kępska M, et al. Szczepienie przeciwko półpaścowi. Zalecenia grupy ekspertów Polskiego Towarzystwa Wakcynologii, Polskiego Towarzystwa Medycyny Rodzinnej, Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Badania Bólu i Polskiego Towarzystwa Neurologicznego, Med. Prakt. 2023; 5: 64–72.
- NFZ o zdrowiu. Raport NFZ. Stwardnienie rozsiane, 2021. https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/raporty/nfz-o-zdrowiu- stwardnienie-rozsiane (12.07.2024).
- Shingrix Summary of Product Characteristics. https://www.ema.europa.eu/pl/documents/product-information/shingrix-epar-product- information pl.pdf (04.07.2024).
- Komunikat Głównego Inspektora Sanitarnego z dnia 27 października 2023 r. w sprawie Programu Szczepień Ochronnych na rok 2024. https://www.gov.pl/web/psse-przasnysz/program-szczepien-ochronnych-na-rok-2024 (04.07.2024).
- Otero-Romero S, Lebrun-Frénay C, Reyes S, et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023; 29(8): 904–925.
- Strezova A, Diez-Domingo J, Shawafi KA, Zoster-049 Study Group, et.al, Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination, Open Forum Infect Dis, 2022, Oct; 9(10): ofac485. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588150/pdf/ofac485.pdf (04.07.2024).
- Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(4): 91–94.
- Obwieszczenie Ministra Zdrowia z dnia 11 grudnia 2023 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. https://dziennikmz.mz.gov.pl/DUM MZ/2023/112/akt.pdf (04.07.2024).
- Informacja o refundacji szczepionki przeciwko półpaścowi w Polsce. Ihttps://szczepienia.pzh.gov.pl/szczepionka-przeciw-polpascowi-objeta-50-refundacja/ (04.07.2024).
